Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants

被引:0
作者
Ken Ogasawara
Jeanelle Kam
Mark Thomas
Liangang Liu
Mary Liu
Yongjun Xue
Sekhar Surapaneni
Leonidas N. Carayannopoulos
Simon Zhou
Maria Palmisano
Gopal Krishna
机构
[1] Bristol Myers Squibb,
[2] Covance Clinical Research Unit,undefined
[3] Inc.,undefined
来源
Cancer Chemotherapy and Pharmacology | 2021年 / 88卷
关键词
Fedratinib; Drug–drug interaction; CYP3A4; Inducer; Rifampin; Efavirenz;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:369 / 377
页数:8
相关论文
共 208 条
[1]  
Furqan M(2013)Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application Biomark Res 1 5-36
[2]  
Mukhi N(2016)Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases Nat Rev Rheumatol 12 25-2613
[3]  
Lee B(2013)JAK/STAT signaling in hematological malignancies Oncogene 32 2601-314
[4]  
Liu D(2018)JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders F1000Res 7 82-906
[5]  
Schwartz DM(2020)Excretion balance and pharmacokinetics following a single oral dose of [(14)C]-fedratinib in healthy subjects Cancer Chemother Pharmacol 86 307-850
[6]  
Bonelli M(2020)Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects Cancer Chemother Pharmacol 85 899-1148
[7]  
Gadina M(2003)Pharmacokinetic interactions with rifampicin: clinical relevance Clin Pharmacokinet 42 819-242
[8]  
O'Shea JJ(2011)Simulation of clinical drug–drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs Drug Metab Dispos 39 1139-9
[9]  
Vainchenker W(2011)Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug–drug interaction trial design Clin Pharmacol Ther 89 234-1001
[10]  
Constantinescu SN(2002)Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans Clin Pharmacol Ther 72 1-898